Bildkälla: Stockfoto

Lifeclean Q1’23: First take – PFAS dominates sales - Redeye

Redeye saw sales that were in line with our expectations. Sales continue to recover, driven by PFAS, which represented 54% of sales in the quarter. The patented Lifeclean products grew by 90% in the quarter. We will likely makes some small positive revisions to our estimates.

Redeye saw sales that were in line with our expectations. Sales continue to recover, driven by PFAS, which represented 54% of sales in the quarter. The patented Lifeclean products grew by 90% in the quarter. We will likely makes some small positive revisions to our estimates.
Börsvärldens nyhetsbrev
ANNONSER